Relapse prevention for alcohol use disorders: combined acamprosate and cue exposure therapy as aftercare.
Lene StryhnMathias Bach LarsenAnna MejldalChristian SibbersenDorthe Grüner NielsenBent NielsenAnette Søgaard NielsenElsebeth StenagerAngelina Isabella MellentinPublished in: Nordic journal of psychiatry (2021)
The study showed that CET both as monotherapy and combined with acamprosate was superior to AAU monotherapy and AAU + acamprosate in reducing alcohol consumption. Only CET + acamprosate was capable of reducing alcohol consumption in the longer term, indicating that anti-craving medication may not impede CET from exerting an effect on alcohol consumption. Trial registration: ClinicalTrials.gov ID: NCT02298751 (24/11-2014).